Preclinical characterization of INCB053914, a novel pan-PIM kinase inhibitor, alone and in combination with anticancer agents, in models of hematologic malignancies
Holly K. Koblish(Incyte (United States)), Peggy Scherle(Incyte (United States))
Cited by 53
Related Papers
Inhibition of Mitogen-Activated Protein Kinase Kinase Blocks T Cell Proliferation But Does Not Induce or Prevent Anergy
|The Journal of Immunology|1998|294
A Potent and Selective Dual Inhibitor of AXL and MERTK Possesses Both Immunomodulatory and Tumor-Targeted Activity
|Frontiers in Oncology|2020|42